Active Filter(s):
Details:
Under the agreement, the registeration, distribution, promotion, market and sell LEDAGA® (chlormethine gel) in Australia, Asia and the Middle East* as a topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (“MF-CTCL”) in adults.
Lead Product(s): Mechlorethamine
Therapeutic Area: Oncology Product Name: Ledaga
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Helsinn Advanced Synthesis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 01, 2022